Short-term intravenous citalopram augmentation in partial/nonresponders with major depression: A randomized placebo-controlled study

International Clinical Psychopharmacology

Volumn 23, Issue 4, 2008, Pages 198-202

  Altamura, Alfredo Carlo ^a   DellOsso, Bernardo ^a   Buoli, Massimiliano ^a   Bosi, Monica ^b   Mundo, Emanuela ^a  

^a UNIVERSITY OF MILAN   (Italy)

^b UNIVERSITY OF MILAN   (Italy)

Author keywords

Augmentation; Intravenous citalopram; Major depressive episode; Selective serotonin reuptake inhibitors; Treatment response

Indexed keywords

CITALOPRAM; ESCITALOPRAM; LITHIUM; PAROXETINE; PLACEBO; SERTRALINE; VALPROIC ACID; ANTIDEPRESSANT AGENT; SEROTONIN UPTAKE INHIBITOR;

ADD ON THERAPY; ADULT; ANALYSIS OF VARIANCE; ANXIETY; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DOSE TIME EFFECT RELATION; DRUG EFFICACY; FATIGUE; FEMALE; HAMILTON SCALE; HUMAN; INSOMNIA; LOW DRUG DOSE; MAJOR DEPRESSION; MALE; MONTGOMERY ASBERG DEPRESSION RATING SCALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REMISSION; SHORT COURSE THERAPY; SIDE EFFECT; TREATMENT RESPONSE; DRUG COMBINATION; DRUG RESISTANCE; INTRAVENOUS DRUG ADMINISTRATION; MIDDLE AGED; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ANTIDEPRESSIVE AGENTS; CITALOPRAM; DEPRESSIVE DISORDER, MAJOR; DRUG RESISTANCE; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; SEROTONIN UPTAKE INHIBITORS;

EID: 54049120666     PISSN: 02681315     EISSN: None     Source Type: Journal    
DOI: 10.1097/YIC.0b013e3282fe9d54     Document Type: Article

References (29)

1. Altamura AC, Zanoni S, Bosi M, Mundo E (2006). Augmentative intravenous clomipramine in partial responder major depressive: a single blind, placebo controlled study. Shown at 159° meeting of the American Psychiatry Association. Toronto, ON.
2. American Psychiatric Association (2000a). Diagnostic and statistical manual of mental disorders. 4th ed. Text Revision. Washington DC: American Psychiatric Association.
3. American Psychiatric Association (2000b). Practice guideline for the treatment of patients with major depressive disorder. Am J Psychiatry 157:1-45.
4. Bauer M (2002). Thyroid hormone augmentation with levothyroxine in bipolar depression. Bipolar Disord 4:109-110.
5. Bauer M, Adli M, Baethge C, Berghöfer A, Sasse J, Heinz A, Bschor T (2003). Lithium augmentation therapy in refractory depression: clinical evidence and neurobiological mechanisms. Can J Psychiatry 48:440-448.
6. Baumann P, Nil R, Bertschy G (1998). A double-blind, double-dummy study of citalopram comparing infusion versus oral administration. J Affect Disord 49:203-210.
7. Blier P, Bergeron R (1995). Effectiveness of pindolol with selected antidepres-sant drugs in the treatment of major depression. J Clin Psychopharmacol 15:217-222.
8. Carpenter LL, Yasmin S, Price LH (2002). A double-blind, placebo-controlled study of antidepressant augmentation with mirtazapine. Biol Psychiatry 51:183-188.
9. Charbonnier JF, Rebuol P, Rougier M, Aubin B, Chassaing JL, Philippe P, et al. (1987). Citalopram: an open trial of a highly selective 5-HT uptake inhibitor, administrated intravenously to depressed patients. L'Encephale 13:249-254.
10. Fava M, Davidsion KG (1996). Definition and epidemiology of treatment-resistant depression. Psychiatr Clin North Am 19:179-200.
11. First MB, Williams JB, Gibbon M, Spitzer RL (1997). Structured clinical interview for DSM-IV axis I (SCID-I), clinician version. Washington DC: American Psychiatric Press.
12. Hamilton M (1960). A rating scale for depression. J Neurol Neurosurgery Psychiatry 23:56-62.
13. Hosaka T, Aoki T, Watanabe T, Okuyama T, Kurosawa H (1999). General hospital psychiatry from the perspective of medical economics. Psychiatry Clin Neurosci 53:449-453.
14. Joffe RT, Schuller DR (1993). An open study of buspirone augmentation of serotonin reuptake inhibitors in refractory depression. J Clin Psychiatry 54:269-271.
15. Jungkunz G, Kuss HJ, Dieterle D (1984). Comparison of intravenous versus oral clomipramine in patients with endogenous depression [In German]. In: Kielholz P, Adams C, editors. Intravenous treatment of depression. Stuttgart: Thieme.
16. Kasper S, Müller-Spahn F (2002). Intravenous antidepressant treatment: focus on citalopram. Eur Arch Psychiatry Clin Neurosci 252:105-109.
17. Montgomery SA, Asberg M (1979). A new depression scale designed to be sensitive to change. Br J Psychiat 134:382-389.
18. Nemeroff CB (1996). Augmentation strategies in patients with refractory depression. Depress Anxiety 4:169-181.
19. Nierenberg AA, DeCecco LM (2001). Definitions of antidepressant treatment response, remission, nonresponse, partial response, and other relevant outcomes: a focus on treatment-resistant depression. J Clin Psychiatry 62: 5-9.
20. Pallanti S, Quercioli L, Koran L (2002). Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J Clin Psychiatry 63:796-801.
21. Paykel ES, Ramana R, Cooper Z, Hayhurst H, Kerr J, Barocka A (1995). Residual symptoms after partial remission: an important outcome in depression. Psychol Med 25:1171-1180.
22. Pollock BG, Perel JM, Nathan RS, Kupfer DJ (1989). Acute antidepressant effect following pulse loading with intravenous and oral clomipramine. Arch Gen Psychiatry 46:29-35.
23. Preskorn SH, Burke M (1992). Somatic therapy for major depressive disorder: selection of an antidepressant. J Clin Psychiatry 53:10.
24. Sackeim HA (2001). The definition and meaning of treatment-resistant depression. J Clin Psychiatry 62:10-17.
25. Stahl SM (2005). Essential psychopharmacology-the prescriber's guide. Cambridge, UK: Cambridge University Press.
26. Stein G, Bernadt M (1993). Lithium augmentation therapy in tricyclic-resistant depression. A controlled trial using lithium in low and normal doses. Br J Psychiatry 162:634-640.
27. Suhara T, Takano A, Sudo Y, Ichimiya T, Inoue M, Yasuno F, et al. (2003). High levels of serotonin transporter occupancy with low-dose clomipramine in comparative occupancy study with fluvoxamine using positron emission tomography. Arch Gen Psychiatry 60:386-391.
28. Thase ME, Fava M, De Battista C, Arora S, Hughes RJ (2006). Modafinil augmentation of SSRI therapy in patients with major depressive disorder and excessive sleepiness and fatigue: a 12 week, open label, extension study. CNS Spectr 11:93-102.
29. Worthington JJ III, Kinry AG, Wygant LE, Pollack MH (2005). Aripripazole as an augmentor of selective serotonin reuptake inhibitors in depression and anxiety disorder patients. Int Clin Psychopharmacol 20:9-11.